Krystal Biotech (NASDAQ:KRYS – Get Free Report) is anticipated to release its earnings data before the market opens on Monday, February 24th. Analysts expect Krystal Biotech to post earnings of $1.29 per share and revenue of $91.35 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Krystal Biotech Stock Performance
NASDAQ:KRYS opened at $153.24 on Monday. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The firm has a market cap of $4.41 billion, a P/E ratio of 86.58 and a beta of 0.84. The firm has a 50-day simple moving average of $158.61 and a 200-day simple moving average of $175.74.
Analyst Ratings Changes
Several research firms have recently commented on KRYS. Chardan Capital restated a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup boosted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $206.67.
Get Our Latest Analysis on KRYS
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by company insiders.
About Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read More
- Five stocks we like better than Krystal Biotech
- Find and Profitably Trade Stocks at 52-Week Lows
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Investing In Automotive Stocks
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now…
Should You Invest $1,000 in Krystal Biotech Right Now?
Before you consider Krystal Biotech, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Krystal Biotech wasn’t on the list.
While Krystal Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Unlock your free copy of MarketBeat’s comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you’ll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street’s top analysts.
